<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01609153</url>
  </required_header>
  <id_info>
    <org_study_id>COMBINE</org_study_id>
    <nct_id>NCT01609153</nct_id>
  </id_info>
  <brief_title>Comparison of Antipsychotic Combination Treatment of Olanzapine and Amisulpride to Monotherapy</brief_title>
  <acronym>COMBINE</acronym>
  <official_title>A Randomized Double-blind Controlled Trial to Assess the Benefits of Olanzapine and Amisulpride Combination Treatment in Acutely Ill Schizophrenia Patients. - COMBINE</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Heinrich-Heine University, Duesseldorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Heinrich-Heine University, Duesseldorf</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A study to examine whether an antipsychotic combination treatment of olanzapine and
      amisulpride is more effective than olanzapine and amisulpride alone.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Polypharmacy in antipsychotic therapy is an important issue when treating patients with
      schizophrenia. It is not well confirmed that a combination of two antipsychotic drugs lead to
      therapeutic benefit in contrast to monotherapy. However there is a highly frequent practice
      of combining atypical non-clozapine treatment that could be due to potential benefits when
      seeking alternatives to a high rate of non-response in acute phase. Therefore there is a need
      for further trials of sufficient power to address efficacy and safety issues of this regimen.
      Combining two selected atypical drugs in a complementary way may minimize side-effects and
      enhance efficacy. In order to specify these advantages it is intend to examine approaches to
      combination treatment: Amisulpride and olanzapine show complementing receptor binding
      profiles and have shown to have efficacy and good tolerability when administered in
      combination in retrospective studies. The object of this trial is to study whether acutely
      ill patients with combination of amisulpride and olanzapine are more frequently in
      symptomatic remission after 8 weeks than those with olanzapine or amisulpride monotherapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">April 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS)</measure>
    <time_frame>8 weeks</time_frame>
    <description>Whether there is a symptomatic improvement of schizophrenia after 8 weeks of treatment in comparison to time of inclusion of patient measured py Positive and Negative Symptom Scale (PANSS)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Symptomatic improvement of schizophrenia after 16 weeks of treatment in comparison to time of inclusion of patient measured py PANSS total score reduction</measure>
    <time_frame>16 weeks.</time_frame>
    <description>To study whether a combination treatment of olanzapine and amisulpride show a PANSS total score reduction from baseline to week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Symptomatic improvement of schizophrenia from baseline to week 2 up to week 16 measured by PANSS total score reduction.</measure>
    <time_frame>Every 2 weeks up to week 16.</time_frame>
    <description>Whether a combination treatment of olanzapine and amisulpride show a PANSS total score reduction from baseline to every 2 weeks up to week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PANSS total score reduction from baseline to week 2 as a predictor of the change after 8 weeks</measure>
    <time_frame>8 weeks</time_frame>
    <description>Whether a change of PANSS total score reduction from baseline to week 2 is a predictor of the change after 8 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serious adverse drug reactions</measure>
    <time_frame>16 weeks</time_frame>
    <description>Frequency and severity of serious adverse drug reactions</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of clinical condition measured by Clinical Global Impression Scale (CGI scale)</measure>
    <time_frame>every 2 weeks from baseline up to week 16</time_frame>
    <description>Whether there is a change of clinical condition measured by Clinical Global Impression Scale (CGI scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of the subjective well-being measured by Subjective Wellbeing under Neuroleptics Scale (SWN-K)</measure>
    <time_frame>between week 0, 8, 16</time_frame>
    <description>Whether there is a change of the subjective well-being measured by Subjective Wellbeing under Neuroleptics Scale(SWN-K)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">399</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Schizoaffective Disorder</condition>
  <arm_group>
    <arm_group_label>Olanzapine or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride or Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olanzapine and Amisulpride</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine</intervention_name>
    <description>Coated tablet 5-20 mg milligram(s) per day for 16 weeks</description>
    <arm_group_label>Amisulpride or Placebo</arm_group_label>
    <arm_group_label>Olanzapine and Amisulpride</arm_group_label>
    <other_name>Zyprexa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>200-800 mg milligram(s)per day for 16 weeks</description>
    <arm_group_label>Olanzapine or Placebo</arm_group_label>
    <arm_group_label>Olanzapine and Amisulpride</arm_group_label>
    <other_name>Amisulprid Hexal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olanzapine and Amisulpride</intervention_name>
    <description>Zyprexa:
Coated tablet 5-20 mg milligram(s) per day for 16 weeks
Amisulpride:
Coated tablet 200-800 mg milligram(s)per day for 16 weeks</description>
    <arm_group_label>Olanzapine or Placebo</arm_group_label>
    <arm_group_label>Amisulpride or Placebo</arm_group_label>
    <other_name>Zyprexa, Amisuprid Hexal</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with schizophrenia and schizoaffective disorder according to International
             Classification of Diseases (ICD-10);

          -  age 18-65;

          -  Positive and Negative Symptom Scale Total-Score ≥ 70 and two items of the positive
             symptom subscale ≥4.

          -  voluntary treatment after written informed consent

          -  legal capacity

          -  exclusion of pregnancy by laboratory test (Beta HCG)

        Exclusion Criteria:

          -  participation in other interventional studies with drugs or medical devices

          -  first episode patients

          -  physical disease that might have effects on the conduct or evaluation of the trial

          -  contraindications to medication according to experts information

          -  oversensitivity to active substance or other component of the drugs used

          -  known clozapine resistance

          -  suicidal ideation

          -  pregnancy or lactation

          -  which of pregnancy or absence save contraception

          -  dependency to sponsor or investigator

          -  institutionalization through judicial or regulatory order

          -  oversensitivity to placebo (mannite/aerosil)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christian Schmidt-Kraepelin, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Heinrich-Heine University, Duesseldorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Christian Schmidt-Kraepelin, Dr.</last_name>
    <phone>0049 211 922</phone>
    <phone_ext>2783</phone_ext>
    <email>christian.schmidt-kraepelin@lvr.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sandra Feyerabend</last_name>
    <phone>0049211922</phone>
    <phone_ext>2796</phone_ext>
    <email>sandra.feyerabend@lvr.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>RWTH Aachen</name>
      <address>
        <city>Aachen</city>
        <zip>52074</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tanja Veselinovic, Dr. med.</last_name>
      <phone>+49-(0)241-8080</phone>
      <phone_ext>0</phone_ext>
      <email>tveselinovic@ukaachen.de</email>
    </contact>
    <contact_backup>
      <last_name>Marc Augustin, Dr. med.</last_name>
      <phone>+49-(0)241-8080</phone>
      <phone_ext>166</phone_ext>
      <email>maugustin@ukaachen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rheinhessen Fachklinik Alzey</name>
      <address>
        <city>Alzey</city>
        <zip>55232</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anke Brockhaus-Dumke, PD Dr. med.</last_name>
      <phone>+49-(0)6731</phone>
      <phone_ext>501212</phone_ext>
      <email>a.brockhaus-dumke@rfk.landeskrankenhaus.de</email>
    </contact>
    <contact_backup>
      <last_name>Siamak Roushanai, Dr. med.</last_name>
      <phone>+49-(0)6731</phone>
      <phone_ext>501593</phone_ext>
      <email>s.roushanai@rfk.landeskrankenhaus.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Rhein-Mosel-Fachklinik Andernach</name>
      <address>
        <city>Andernach</city>
        <zip>56626</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Konrad, PD Dr. med.</last_name>
      <phone>+49-(0)2632-407</phone>
      <phone_ext>5534</phone_ext>
      <email>a.konrad@rmf.landeskrankenhaus.de</email>
    </contact>
    <contact_backup>
      <last_name>Stefan Elsner, Dr. med.</last_name>
      <phone>+49-(0)2632-407</phone>
      <phone_ext>5412</phone_ext>
      <email>s.elsner@rmf.landeskrankenhaus.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Bezirkskliniken Schwaben, Bezirkskrankenhaus Augsburg</name>
      <address>
        <city>Augsburg</city>
        <zip>89156</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Susanne Baumgärtner</last_name>
      <phone>+49-0821-4803</phone>
      <phone_ext>1021</phone_ext>
      <email>wissenschaftsabteilung@bkh-augsburg.de</email>
    </contact>
    <contact_backup>
      <last_name>Marianne Bärhold, Dr.</last_name>
      <phone>+49-0821-4803</phone>
      <phone_ext>3770</phone_ext>
      <email>wissenschaftsabteilung@bkh-augsburg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Charite-Universitätsmedizin Berlin</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>LWL-Klinik Dortmund</name>
      <address>
        <city>Dortmund</city>
        <zip>44281</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hans-Jörg Assion, Prof. Dr.</last_name>
      <phone>+49-(0)231-45092673</phone>
      <email>hans-joerg.assion@wkp-wl.org</email>
    </contact>
    <contact_backup>
      <last_name>Gerhard Reymann, PD Dr.</last_name>
      <email>gerhard.reymann@lwl.org</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>LVR-Klinikum Düsseldorf</name>
      <address>
        <city>Düsseldorf</city>
        <zip>40629</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Schmidt-KraepelinCordes, Dr.</last_name>
      <phone>+49-(0)211-922</phone>
      <phone_ext>2783</phone_ext>
      <email>christian.schmidt-kraepelin@lvr.de</email>
    </contact>
    <contact_backup>
      <last_name>Joachim Cordes, PD Dr.</last_name>
      <phone>+49-(0)211-922</phone>
      <phone_ext>3402</phone_ext>
      <email>joachim.cordes@lvr.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Zentrum für Seelische Gesundheit Kreiskliniken Darmstadt-Dieburg Standort: Groß-Umstadt</name>
      <address>
        <city>Groß-Umstadt</city>
        <zip>64823</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas Wobrock, Prof. MD</last_name>
      <phone>+49-(0)6078-79</phone>
      <phone_ext>2901</phone_ext>
      <email>t.wobrock@kreiskliniken-dadi.de</email>
    </contact>
    <contact_backup>
      <last_name>Jens Edinger</last_name>
      <email>j.edinger@kreiskliniken-dadi.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Göttingen</name>
      <address>
        <city>Göttingen</city>
        <zip>37075</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernhard Kis, Dr.</last_name>
      <phone>+49-(0)551-3910114</phone>
      <email>Bernhard.Kis@med.uni-goettingen.de</email>
    </contact>
    <contact_backup>
      <last_name>David Zilles, Dr.</last_name>
      <email>dzilles@gwdg.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Psychotherapie und Psychosomatik am Bezirkskrankehaus Günzburg</name>
      <address>
        <city>Günzburg</city>
        <zip>89312</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Klinik für Psychiatrie, Sozialpsychiatrie und Psychotherapie Medizinische Hochschule Hannover (MHH)</name>
      <address>
        <city>Hannover</city>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kai Kahl, Prof. Dr.</last_name>
      <phone>0049511532</phone>
      <phone_ext>2495</phone_ext>
      <email>kahl.kai@mh-hannover.de</email>
    </contact>
    <contact_backup>
      <last_name>Helge Frieling, Prof. Dr.</last_name>
      <phone>0049511532</phone>
      <phone_ext>2495</phone_ext>
      <email>frieling.helge@mh-hannover.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69115</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>LVR-Klinikum Köln</name>
      <address>
        <city>Köln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dirk Reske, Dr.</last_name>
      <phone>+49-(0)2218993</phone>
      <phone_ext>797</phone_ext>
      <email>dirk.reske@lvr.de</email>
    </contact>
    <contact_backup>
      <last_name>Ulrike Reinholz, Dr.</last_name>
      <phone>+49-(0)2218993</phone>
      <phone_ext>0</phone_ext>
      <email>ulrike.reinholz@lvr.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>LVR-Klinik Langenfeld</name>
      <address>
        <city>Langenfeld</city>
        <zip>40764</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Neff, Dr.</last_name>
      <phone>+49-(0)2173102</phone>
      <phone_ext>0</phone_ext>
      <email>andrea.neff@lvr.de</email>
    </contact>
    <contact_backup>
      <last_name>Martina Pellio-Blume, Dr.</last_name>
      <phone>+49-(0)2173102</phone>
      <phone_ext>0</phone_ext>
      <email>martina.pellio-blume@lvr.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Leipzig, Klinik und Poliklinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Kluge, Dr</last_name>
      <phone>00493419724</phone>
      <phone_ext>673</phone_ext>
      <email>michael.kluge@medizin.uni-leipzig.de</email>
    </contact>
    <contact_backup>
      <last_name>Jens Dietzel, Dr.</last_name>
      <phone>00493419724</phone>
      <phone_ext>530</phone_ext>
      <email>jens.dietzel@medizin.uni-leipzig.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsmedizin Mainz Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Mainz</city>
        <zip>55131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Zentralinstitut für Seelische Gesundheit</name>
      <address>
        <city>Mannheim</city>
        <zip>68159</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gerhard Gründer, Prof. MD</last_name>
      <phone>+49-(0)621-1703</phone>
      <phone_ext>2911</phone_ext>
      <email>Gerhard.Gruender@zi-mannheim.de</email>
    </contact>
    <contact_backup>
      <last_name>Mathias Zink, Prof. MD</last_name>
      <phone>+49-(0)621-1703</phone>
      <phone_ext>2911</phone_ext>
      <email>Mathias.Zink@zi-mannheim.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>LMU München</name>
      <address>
        <city>München</city>
        <zip>80336</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Falkai, Prof. Dr.</last_name>
      <phone>+49-(0)89-5160</phone>
      <phone_ext>5501</phone_ext>
      <email>Peter.Falkai@med.uni-muenchen.de</email>
    </contact>
    <contact_backup>
      <last_name>Berend Malchow, Dr.</last_name>
      <phone>+49-(0)89-4400</phone>
      <phone_ext>55331</phone_ext>
      <email>Berend.Malchow@med.uni-muenchen.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>TU München</name>
      <address>
        <city>München</city>
        <zip>81675</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Suspended</status>
  </location>
  <location>
    <facility>
      <name>Bezirksklinikum Regensburg, Klinik für Psychiatrie und Psychotherapie</name>
      <address>
        <city>Regensburg</city>
        <zip>93053</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Berthold Langguth, PD Dr. med.</last_name>
      <phone>+49-(0)941941</phone>
      <phone_ext>2099</phone_ext>
      <email>berthold.langguth@medbo.de</email>
    </contact>
    <contact_backup>
      <last_name>Elmar Frank, Dr.</last_name>
      <phone>+49-(0)941941</phone>
      <phone_ext>0</phone_ext>
      <email>elmar.frank@medbo.de</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 23, 2012</study_first_submitted>
  <study_first_submitted_qc>May 29, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 31, 2012</study_first_posted>
  <last_update_submitted>May 11, 2018</last_update_submitted>
  <last_update_submitted_qc>May 11, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>amisulpride</keyword>
  <keyword>olanzapine</keyword>
  <keyword>polypharmacy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olanzapine</mesh_term>
    <mesh_term>Sultopride</mesh_term>
    <mesh_term>Sulpiride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

